While the STAR SIGN study found decreased CMIR among those on anti-TNF therapy, the Impact of Biologic and Immunomodulatory Therapy on SARS-CoV-2 Infection and Immunity in Patients with IBD (CLARITY-IBD), Coronavirus Risk Associations and Longitudinal Evaluation-IBD, and HERCULES study groups found that patients with IBD on anti-TNF therapy have similar or augmented CMIR following vaccination with the primary series. The gene discussed is TNF; the disease is inflammatory bowel disease.